Literature DB >> 14720081

A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy.

Andrea Tramarin1, Stefano Campostrini, Maarten J Postma, Guido Calleri, Keith Tolley, Nicoletta Parise, Fausto de Lalla.   

Abstract

OBJECTIVE: To describe the epidemiological, clinical and economic changes that occurred in the HIV epidemic in Italy prior to and after the introduction of highly active antiretroviral therapy (HAART).
DESIGN: A prospective, observational, multicentre case-control study was conducted comparing data, collected over 6 months, from an AIDS cohort in 1998 with that of a cohort in 1994. Out of 77 patients with AIDS in the 1998 cohort, 74 survived. These 74 patients were matched for severity of illness with 74 patient survivors from the 1994 cohort to enable valid comparisons of mortality, disability-dependency (DD), health-related QOL (HR-QOL), and direct costs.
RESULTS: Overall, a considerable difference was observed in mortality (33.8% in 1994 vs 3.9% in 1998) between unmatched patients of the two cohorts. As for matched patients, the number of hospital admissions was 1.7 in 1994 and 0.8 in 1998; the average length of stay was 28.1 days in 1994 and 12.6 days in 1998. The direct cost per patient per year was euro15 390 and euro11 465 for the 1994 and 1998 cohorts, respectively (1999 values). The 1998 patient cohort had significantly better HR-QOL at 6 months in two domains of the instrument used (emotional reaction and energy) and the percentage of totally dependent patients was significantly lower compared with the 1994 cohort (1.4% vs 6.8%).
CONCLUSIONS: This is the first study to present a comprehensive comparison of direct costs, DD and HR-QOL of patients with AIDS between two time periods. The use of a case-control design has enabled changes in costs and outcomes to be linked to the introduction of HAART in Italy in 1997.

Entities:  

Mesh:

Year:  2004        PMID: 14720081     DOI: 10.2165/00019053-200422010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

Review 1.  Cost effectiveness of combination HIV therapy: 3 years later.

Authors:  R D Moore
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

2.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

3.  Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Authors:  J Cook; E Dasbach; P Coplan; L Markson; D Yin; A Meibohm; B Y Nguyen; J Chodakewitz; J Mellors
Journal:  AIDS Res Hum Retroviruses       Date:  1999-04-10       Impact factor: 2.205

4.  Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.

Authors:  P T Nieuwkerk; E H Gisolf; R Colebunders; A W Wu; S A Danner; M A Sprangers
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

5.  Why we need observational studies to evaluate the effectiveness of health care.

Authors:  N Black
Journal:  BMJ       Date:  1996-05-11

6.  Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.

Authors:  D A Revicki; G Moyle; H J Stellbrink; C Barker
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

7.  Efficiency and rationality in the planning of health care for people with AIDS: an application of the balance of care approach. North-East Italian Group for Planning of AIDS Health Care.

Authors:  A Tramarin; K Tolley; S Campostrini; F de Lalla
Journal:  AIDS       Date:  1997-05       Impact factor: 4.177

8.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

9.  Disease-staging for modelling current and future health-care impact of disease: illustrations for diabetes mellitus and AIDS.

Authors:  M J Postma; J C Jager; D Ruwaard; N C van Loy; R M Leidl
Journal:  Health Policy       Date:  1998-01       Impact factor: 2.980

10.  Costs of HIV medical care in the era of highly active antiretroviral therapy.

Authors:  K A Gebo; R E Chaisson; J G Folkemer; J G Bartlett; R D Moore
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

View more
  11 in total

1.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Authors:  Andrew M Hill; Kelly Gebo; Lindsay Hemmett; Mickael Löthgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lindsay Hemmett; Jonas Hjelmgren; Gabriele Allegri; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.

Authors:  Caroline E Sloan; Karen Champenois; Philippe Choisy; Elena Losina; Rochelle P Walensky; Bruce R Schackman; Faiza Ajana; Hugues Melliez; A D Paltiel; Kenneth A Freedberg; Yazdan Yazdanpanah
Journal:  AIDS       Date:  2012-01-02       Impact factor: 4.177

5.  The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution.

Authors:  Eugene Mutimura; Aimee Stewart; Nigel J Crowther; Kevin E Yarasheski; W Todd Cade
Journal:  Qual Life Res       Date:  2008-03-05       Impact factor: 4.147

6.  The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care.

Authors:  Edward M Gardner; Moises E Maravi; Cornelis Rietmeijer; Arthur J Davidson; William J Burman
Journal:  Appl Health Econ Health Policy       Date:  2008       Impact factor: 2.561

Review 7.  A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.

Authors:  Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain.

Authors:  Juan Oliva-Moreno; Julio López-Bastida; Pedro Serrano-Aguilar; Lilisbeth Perestelo-Pérez
Journal:  Eur J Health Econ       Date:  2010-01-05

10.  Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study.

Authors:  Goedele M Louwagie; Max O Bachmann; Kobus Meyer; Frikkie le R Booysen; Lara R Fairall; Christo Heunis
Journal:  BMC Public Health       Date:  2007-09-14       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.